Nexien BioPharma, Inc. (OTCPK: NXEN)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Nexien BioPharma, Inc. (OTCPK: NXEN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $7.08K and employs 10 people.
trading between 0.00 and 0.01.
Tweenvest scores Nexien BioPharma, Inc. across four factors: quality 5/100. Its strongest factor is quality.
NXEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.08K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.88
- 52-week high
- $0.01
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 70.77M
- Employees
- 10
- Next earnings
- —
About Nexien BioPharma, Inc.
Nexien BioPharma, Inc., a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders. It adopted its current name in September 2018, having previously operated as Intiva BioPharma Inc.
- ISIN
- US65343D1000
- Listed since
- Nov 29, 2017
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.